
















Dolan et al.

**Figure 4.**

Association of lower *RPRD1B* expression and CisIPN. Box and cumulative incidence plots of PrediXcan-predicted *RPRD1B* expression by neuropathy status reveal that lower expression correlates with neuropathy in (A) the Platinum Study's TCS cohort ( $P = 3.6 \times 10^{-6}$ ), and (B) Vanderbilt's BioVU cohort (one-tailed  $P = 0.021$ ) and (C) the CALGB 90401 docetaxel trial (one-tailed  $P = 0.055$ ). In A and B, the centers of the boxplots indicate means, the hinges indicate interquartile regions (IQR), the whiskers indicate points within  $1.5 \times$  IQR. Data beyond the end of the whiskers are outliers plotted as points. In B, logistic regression was performed in BioVU to assess the association between PrediXcan expression and the code for polyneuropathy due to drugs—1 for cases ( $n = 20$ ), 0 for controls ( $n = 18,600$ ). In C, Cox proportional hazards regression was performed to assess the association between PrediXcan expression and a dose-to-grade 3 or higher neuropathy event in the CALGB. An arbitrary cutoff is used to illustrate the association between the continuous gene expression variable and the dose-to-event phenotype: Individuals were ranked according to gene expression as determined by PrediXcan and the first quartile refers to the 25% with the lowest genetically determined *RPRD1B* expression and second to fourth refer to the remaining individuals. Replication was assessed by the Fisher combined  $P$  value of both replications (BioVU and CALGB) and met significance ( $P = 0.0089$ ).

variables. The cross-sectional design prevents conclusions as to whether these associated variables are risk factors or consequences of CisIPN which would require a prospective design. We found significant heritability, indicating that genetic variants could explain a large proportion of variability in the phenotype. Aggregating SNP effects using PrediXcan (31), a gene-level test imputing genetically regulated expression from genotypes, revealed lower expression of *MIDN* in skin and *RPRD1B* in whole blood, as well as higher expression of *THEM5* in tibial nerve as genome-wide significant. Using two independent datasets, we replicated the finding that lower *RPRD1B* predicted expression is associated with drug-induced neurop-

athy using predictors from whole blood, investigating a docetaxel-induced neuropathy phenotype and a broader drug-induced polyneuropathy phenotype in EHR.

#### PrediXcan

PrediXcan is a recently developed gene-based method that tests the genetically determined component of gene expression in a given tissue for association with a phenotype (31). The use of genetically determined gene expression to identify trait-associated genes is supported by evidence that SNPs associated with chemotherapeutic drug susceptibility (42) and complex traits (43) are more likely to be sites that associate with gene



expression. Furthermore, an observed association with the genetic component proposes a causal direction of effect because the phenotype does not alter the germline genetic profile. We theorized that tibial nerve, skin, and whole blood best represent neuronal tissue and the microenvironment surrounding nerves and their endings, a potentially important source of variability in CIPN. Because genetic regulation of gene expression can be non-tissue specific, the Bonferroni correction (correcting for the total number of tests across the tissues) is conservative. In three of the four tissues tested, lower expression of *RPRD1B* is associated with CisIPN at  $P < 10^{-4}$ , illustrating substantial tissue-shared genetic regulation. Vanderbilt's BioVU identified lower predicted gene expression of *RPRD1B* in the discovery tissue (DGN whole blood) as associated with drug-induced polyneuropathy. However, the analysis could not distinguish drug classes. Further suggestive association of neuropathy with lower expression of *RPRD1B* in the CALGB 90401 may indicate that the mechanism for the association is not drug-specific, as that trial investigated neuropathy induced by docetaxel, another neurotoxic chemotherapeutic agent with a distinct mechanism of cytotoxicity. Therefore, *RPRD1B* might have broad implications in CIPN.

#### RPRD1B

Twenty SNPs in four distinct linkage disequilibrium blocks ( $R^2 < 0.5$ ) 36 to 37.5 kb into chromosome 20 predict *RPRD1B* expression. *RPRD1B* codes for Kub5-Hera, a protein regulating the binding of RNA polymerase II to *CCND1* gene (cyclin D1), and regulating the transcription of several genes involved in the cell cycle (44). Emerging data indicate that *RPRD1B* plays an important role in several DNA repair mechanisms, including double-strand breaks (DSBs) repair through the association with core nonhomologous end-joining (NHEJ) proteins (45) and mismatch repair (46). Defects in *RPRD1B* expression or knockdown cause a deficiency in DNA repair mechanisms known to be critical in resolving cisplatin-induced lesions (47). Consistent with our data indicating low levels of *RPRD1B* being associated with CisIPN, knockdown of this gene in a breast cancer cell line, MDA-123, results in increased sensitivity to cisplatin (45). However, the suggestive association of *RPRD1B* with docetaxel-induced neuropathy indicates that other mechanisms may be important. *RPRD1B* functions as a coactivator of the  $\beta$ -catenin-TCF complex to enhance the transcriptional activity of Wnt signaling (48). Wnt signaling is critical for initial neural cell-fate determination, patterning and synapse formation of sensory neurons of the dorsal root ganglia. This signaling pathway is also active in adult sensory neurons and modulates sensitivity to nociceptive stimuli (49, 50). Mechanistic insights into the function of *RPRD1B* are warranted to assess its role in the pathophysiology of neurotoxicity, possibly revealing novel targets.

#### Demographic and clinical factors and health behaviors

Our study identified age, smoking, excess alcohol use, and hypertension as associated with CisIPN. The relationship with age is consistent with several previous reports of taxane-induced neuropathy, including ECOG 5103 (4, 8, 36). In contrast, a number of studies of oxaliplatin-treated patients did not find an association with age (6, 7).

**Tobacco and alcohol use.** Few studies have addressed the role of tobacco use in CIPN. The authors of one study that found a

correlation between smoking and CIPN postulated that long-term heavy smoking reduces peripheral blood flow, likely exacerbating paclitaxel-induced neuropathy (5). Conversely, a study of 730 TCS given platinum-based chemotherapy (9) and another of 62 patients with colon cancer receiving oxaliplatin reported no association (7). Among 169 patients given oxaliplatin-based chemotherapy, alcohol consumption was associated with neuropathy (6). In contrast, two studies in patients with breast cancer found no such relation of CIPN (10, 11). Alcohol-related peripheral neuropathy is a complication affecting up to half of alcoholic individuals (51). Excess alcohol use also plays a role in the development and progression of diabetic neuropathy (52).

**Hypertension.** In our study, the association between hypertension and CIPN was of borderline significance in multivariate analyses. Hypertension was not significantly associated with CIPN in the studies by Hershman and colleagues (4) and Glendenning and colleagues (9). One could postulate that microvascular complications associated with hypertension may contribute to CIPN, but our findings remain to be confirmed in other studies.

**Lower physical activity and weight gain.** We found CisIPN was associated with lower physical activity levels and greater weight gain since chemotherapy completion. Although a longitudinal study design would be best for establishing causal inferences, it is possible that CIPN symptoms could deter from physical activity and thereby promote weight gain. Known downstream effects of weight gain include obesity, diabetes, and other medical complications. Another long-term study in TCS has shown other comorbidities are associated with CIPN, including neuroticism (53), further emphasizing the clinical impact of CIPN symptoms and their effects on patient health.

#### Strengths and limitations

A major strength of our study consists of its comprehensive assessment of a variety of clinical and genetic factors associated with CisIPN. Other strengths include the homogeneity of cisplatin-based chemotherapy without the administration of other neurotoxic drugs, detailed data on cisplatin dose, and the high patient participation rate (93%). Patient reported outcomes were carefully considered, and for the CisIPN phenotype, the validated EORTC QLQ-CIPN20 questionnaire (20) was applied. Although a number of studies of CIPN (reviewed above) considered the influence of one or a few covariates on CIPN, the present investigation considered all variables taken together. In addition, to our knowledge, no other study has considered the impact of CIPN on self-reported health or reported associations with weight gain and physical activity. PrediXcan (31), a state-of-the-art gene-based method implicated *RPRD1B*, a gene known to play an important role in DNA repair mechanisms involved in cisplatin-induced damage, and shown to increase cisplatin sensitivity upon knockdown (45). Predictions are most helpful for variables known prior to treatment, yet as in previous studies (15, 18, 38, 39), baseline data before treatment were not collected. Any cross-sectional study design has potential inherent limitations and does not allow us to infer causation of other evaluated risk factors for CisIPN, but rather to report important associations.

Another limitation in this study is the underpowered statistical analyses, as only 85 out of 680 reported severe CisIPN,

Dolan et al.

although a larger proportion reported moderate symptoms (297 of 680). A larger sample size would allow better estimation of the effects of clinical factors and SNPs and would enable making meaningful inferences about phenotype heritability which is limited by large standard errors here. Last, in replicating our study in a large set of EHR, we found lower predicted gene expression of *RPRD1B* to be associated with drug-induced polyneuropathy; however, this phenotype was not able to distinguish specific drug classes.

## Conclusions

In view of the significant associations we found between smoking, excess alcohol use, decreased physical activity, and weight gain with CisIPN, health care providers should promote a healthy lifestyle among patients with CisIPN. The borderline significant association we observed for hypertension and CisIPN remains to be confirmed in other studies, but nonetheless, in view of the highly significant relationship we previously reported between hypertension and hearing loss in TCS (37), health care providers should carefully monitor blood pressure.

There are currently no agents available to prevent or treat CIPN (12), which in our cisplatin-treated population, and as reported by others (9), persists long term. This observation underscores the importance of identifying at-risk patients prior to the administration of chemotherapy, which is currently not possible. Significant heritability indicates that a large proportion of variability in toxicity could be explained by genetic variants, but larger samples are needed to reduce the standard error before variants can be used in clinical prediction. Future research efforts should continue to elucidate the genetic underpinnings of CIPN, with our investigation now showing the importance of using functional genomic information such as expression data in genome-wide analyses to improve power and provide mechanistic explanations. Such approaches are more robust than reporting single polymorphisms with small-to-moderate effect sizes, which require larger datasets and are less clinically impactful. In addition, future research efforts should continue to provide the underpinnings for the eventual development of risk prediction models for CIPN that take into account not only genetic influences but also clinical, demographic, and other important covariates. Our study provides one such example of a comprehensive approach. Future efforts will focus on independent replication in a similarly characterized TCS cohort and evaluation of the predictive power of the variables associated in this study to potentially translate models of CisIPN prediction into the clinic.

## Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

## Authors' Contributions

**Conception and design:** M.E. Dolan, O.E. Charif, H.E. Wheeler, E.R. Gamazon, M. Kubo, N.J. Cox, L.B. Travis

**Development of methodology:** O.E. Charif, H.E. Wheeler, E.R. Gamazon, S.D. Fossa, M. Kubo, N.J. Cox

**Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.):** M.E. Dolan, D.R. Feldman, R.J. Hamilton, D.J. Vaughn, C.J. Beard, C. Fung, D.L. Hertz, T. Mushirola, M. Kubo, L.B. Travis

**Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis):** M.E. Dolan, O.E. Charif, H.E. Wheeler, E.R. Gamazon, S. Ardeshir-Rouhani-Fard, D.R. Feldman, C.J. Beard, L.H. Einhorn, N.J. Cox, L.B. Travis

**Writing, review, and/or revision of the manuscript:** M.E. Dolan, O.E. Charif, H.E. Wheeler, E.R. Gamazon, S. Ardeshir-Rouhani-Fard, D.R. Feldman, R.J. Hamilton, D.J. Vaughn, C.J. Beard, C. Fung, S.D. Fossa, D.L. Hertz, L.H. Einhorn, N.J. Cox, L.B. Travis

**Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases):** M.E. Dolan, M. Kubo, L.H. Einhorn, L.B. Travis

**Study supervision:** M.E. Dolan, S.D. Fossa, M. Kubo, L.B. Travis

**Other (contributed cases and was involved with all aspects of the study):** L.H. Einhorn

## Acknowledgments

We are grateful to Drs. Chen Jiang, Kouros Owzar, and Howard McLeod for intellectual contributions related to the CALGB90401 study. We are grateful to Ryan Cook and Eileen Johnson for technical assistance.

## Grant Support

This work was supported by the NIH, NCI (1 R01 CA157823 to L.B. Travis). In addition, support was provided by Pharmacogenomics Research Network (PGRN)-RIKEN Global Alliance (GM115370), the Riken Center for Integrative Medical Science, Japan, the University of Chicago Cancer Research Foundation Women's Board (to M.E. Dolan), the GTEX Project (R01 MH090937), and the Conte Center for Neuropsychiatric Genomics (P50 MH094267). The Genotype-Tissue Expression (GTEx) Project was supported by the Common Fund of the Office of the Director of the National Institutes of Health. Additional funds were provided by the NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS. Donors were enrolled at Biospecimen Source Sites funded by NCI\SAIC-Frederick, Inc. (SAIC-F) subcontracts to the National Disease Research Interchange (10XS170), Roswell Park Cancer Institute (10XS171), and Science Care, Inc. (X10S172). The Laboratory, Data Analysis, and Coordinating Center (LDACC) was funded through a contract (HHSN268201000029C) to The Broad Institute, Inc. Biorepository operations were funded through an SAIC-F subcontract to Van Andel Institute (10ST1035). Additional data repository and project management were provided by SAIC-F (HHSN261200800001E). The Brain Bank was supported by a supplement to University of Miami grants DA006227 and DA033684 and to contract N01MH000028. Statistical Methods development grants were made to the University of Geneva (MH090941 and MH101814), the University of Chicago (MH090951, MH090937, MH101820, and MH101825), the University of North Carolina–Chapel Hill (MH090936 and MH101819), Harvard University (MH090948), Stanford University (MH101782), Washington University St Louis (MH101810), and the University of Pennsylvania (MH101822). The GTEx datasets used in this manuscript were obtained from dbGaP through accession number phs000424.v6.p1. The data set used for the CALGB 90401–Genome-wide Pharmacogenomic Study of docetaxel and bevacizumab in Hormone Refractory Prostate Cancer described in this article were obtained from dbGaP at (<https://www.ncbi.nlm.nih.gov/gap>) through dbGaP study accession (phs001002.v1.p1).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received December 22, 2016; revised April 17, 2017; accepted June 6, 2017; published OnlineFirst June 13, 2017.

## References

- Argyriou AA, Bruna J, Marmiroli P, Cavaletti G. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. *Crit Rev Oncol Hematol* 2012;82:51–77.
- Brewer JR, Morrison G, Dolan ME, Fleming GF. Chemotherapy-induced peripheral neuropathy: current status and progress. *Gynecol Oncol* 2016; 140:176–83.

3. Avan A, Postma TJ, Ceresa C, Avan A, Cavaletti G, Giovannetti E, et al. Platinum-induced neurotoxicity and preventive strategies: past, present, and future. *Oncologist* 2015;20:411–32.
4. Hershman DL, Till C, Wright JD, Awad D, Ramsey SD, Barlow WE, et al. Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65 years or older in Southwest Oncology Group Clinical Trials. *J Clin Oncol* 2016;34:3014–22.
5. Kawakami K, Tunoda T, Takiguchi T, Shibata K, Ohtani T, Kizu J, et al. Factors exacerbating peripheral neuropathy induced by paclitaxel plus carboplatin in non-small cell lung cancer. *Oncol Res* 2012;20:179–85.
6. Vincenzi B, Frezza AM, Schiavon G, Spoto C, Silvestris N, Addeo R, et al. Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV. *Support Care Cancer* 2013;21:1313–9.
7. Uwah AN, Ackler J, Leighton JC Jr, Pomerantz S, Tester W. The effect of diabetes on oxaliplatin-induced peripheral neuropathy. *Clin Colorectal Cancer* 2012;11:275–9.
8. Schneider BP, Li L, Radovich M, Shen F, Miller KD, Flockhart DA, et al. Genome-wide association studies for taxane-induced peripheral neuropathy in ECOG-5103 and ECOG-1199. *Clin Cancer Res* 2015;21:5082–91.
9. Glendenning JL, Barbachano Y, Norman AR, Dearnaley DP, Horwich A, Huddart RA. Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer. *Cancer* 2010;116:2322–31.
10. Pereira S, Fontes F, Sonin T, Dias T, Fragoso M, Castro-Lopes JM, et al. Chemotherapy-induced peripheral neuropathy after neoadjuvant or adjuvant treatment of breast cancer: a prospective cohort study. *Support Care Cancer* 2016;24:1571–81.
11. Eckhoff L, Feddersen S, Knoop AS, Ewertz M, Bergmann TK. Docetaxel-induced neuropathy: a pharmacogenetic case-control study of 150 women with early-stage breast cancer. *Acta Oncol* 2015;54:530–7.
12. Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. *J Clin Oncol* 2014;32:1941–67.
13. Einhorn LH. Curing metastatic testicular cancer. *Proc Natl Acad Sci U S A* 2002;99:4592–5.
14. Travis LB, Fossa SD, Sesso HD, Frisina RD, Herrmann DN, Beard CJ, et al. Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics. *J Natl Cancer Inst* 2014;106 pii: dju044. doi: 10.1093/jnci/dju044.
15. Kim HS, Kim MK, Chung HH, Kim JW, Park NH, Song YS, et al. Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study. *Gynecol Oncol* 2009;113:264–9.
16. Khrunin AV, Moiseev A, Gorbunova V, Limborska S. Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. *Pharmacogenomics J* 2010;10:54–61.
17. Khrunin AV, Khokhrin DV, Moiseev AA, Gorbunova VA, Limborska SA. Pharmacogenomic assessment of cisplatin-based chemotherapy outcomes in ovarian cancer. *Pharmacogenomics* 2014;15:329–37.
18. Oldenburg J, Kraggerud SM, Brydoy M, Cvancarova M, Lothe RA, Fossa SD. Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-S-transferase-P1 and -M1, a retrospective cross sectional study. *J Transl Med* 2007;5:70.
19. Cavaletti G, Cornblath DR, Merkies IS, Postma TJ, Rossi E, Frigeni B, et al. The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. *Ann Oncol* 2013;24:454–62.
20. Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, et al. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. *Eur J Cancer* 2005;41:1135–9.
21. Cronbach L. Coefficient alpha and the internal structure of tests. *Psychometrika* 1951;16:297–334.
22. Leal AD, Qin R, Atherton PJ, Haluska P, Behrens RJ, Tiber CH, et al. North Central Cancer Treatment Group/Alliance trial N08CA—the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study. *Cancer* 2014;120:1890–7.
23. Gaist D, Jeppesen U, Andersen M, Garcia Rodriguez LA, Hallas J, Sindrup SH. Statins and risk of polyneuropathy: a case-control study. *Neurology* 2002;58:1333–7.
24. Taylor HL, Jacobs DR Jr, Schucker B, Knudsen J, Leon AS, Debacker G. A questionnaire for the assessment of leisure time physical activities. *J Chronic Dis* 1978;31:741–55.
25. Chasan-Taber S, Rimm EB, Stampfer MJ, Spiegelman D, Colditz GA, Giovannucci E, et al. Reproducibility and validity of a self-administered physical activity questionnaire for male health professionals. *Epidemiology* 1996;7:81–6.
26. Wheeler HE, Gamazon ER, Frisina RD, Perez-Cervantes C, El Charif O, Mapes B, et al. Variants in WFS1 and other Mendelian deafness genes are associated with cisplatin-associated ototoxicity. *Clin Cancer Research*. In press, Dec 30, 2016. doi: 10.1158/1078-0432. [Epub ahead of print].
27. Patterson N, Price AL, Reich D. Population structure and eigenanalysis. *PLoS Genet* 2006;2:e190.
28. Howie B, Fuchsberger C, Stephens M, Marchini J, Abecasis GR. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. *Nat Genet* 2012;44:955–9.
29. Aschard H, Vilhjalmsson BJ, Joshi AD, Price AL, Kraft P. Adjusting for heritable covariates can bias effect estimates in genome-wide association studies. *Am J Hum Genet* 2015;96:329–39.
30. Yang J, Lee SH, Goddard ME, Visscher PM. GCTA: a tool for genome-wide complex trait analysis. *Am J Hum Genet* 2011;88:76–82.
31. Gamazon ER, Wheeler HE, Shah KP, Mozaffari SV, Aquino-Michaels K, Carroll RJ, et al. A gene-based association method for mapping traits using reference transcriptome data. *Nat Genet* 2015;47:1091–8.
32. Battle A, Mostafavi S, Zhu X, Potash JB, Weissman MM, McCormick C, et al. Characterizing the genetic basis of transcriptome diversity through RNA-sequencing of 922 individuals. *Genome Res* 2014;24:14–24.
33. Consortium GT. The Genotype-Tissue Expression (GTEx) project. *Nat Genet* 2013;45:580–5.
34. Denny JC, Ritchie MD, Basford MA, Pulley JM, Bastarache L, Brown-Gentry K, et al. PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations. *Bioinformatics* 2010;26:1205–10.
35. Denny JC, Bastarache L, Ritchie MD, Carroll RJ, Zink R, Mosley JD, et al. Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. *Nat Biotechnol* 2013;31:1102–10.
36. Hertz DL, Owzar K, Lessans S, Wing C, Jiang C, Kelly WK, et al. Pharmacogenetic discovery in CALGB (Alliance) 90401 and mechanistic validation of a VAC14 polymorphism that increases risk of docetaxel-induced neuropathy. *Clin Cancer Res* 2016;22:4890–900.
37. Frisina RD, Wheeler HE, Fossa SD, Kerns SL, Fung C, Sesso HD, et al. Comprehensive audiometric analysis of hearing impairment and tinnitus after cisplatin-based chemotherapy in survivors of adult-onset cancer. *J Clin Oncol* 2016;34:2712–20.
38. Goekkur E, Al-Batran SE, Hartmann JT, Mogck U, Schuch G, Kramer M, et al. Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. *J Clin Oncol* 2009;27:2863–73.
39. Lamba JK, Fridley BL, Ghosh TM, Yu Q, Mehta G, Gupta P. Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung cancer. *Pharmacogenomics* 2014;15:1565–74.
40. Hershman DL, Weimer LH, Wang A, Kranwinkel G, Brafman L, Fuentes D, et al. Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. *Breast Cancer Res Treat* 2011;125:767–74.
41. Wolf SL, Barton DL, Qin R, Wos EJ, Sloan JA, Liu H, et al. The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA. *Support Care Cancer* 2012;20:625–32.
42. Gamazon ER, Huang RS, Cox NJ, Dolan ME. Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci. *Proc Natl Acad Sci U S A* 2010;107:9287–92.

Dolan et al.

43. Nicolae DL, Gamazon E, Zhang W, Duan S, Dolan ME, Cox NJ. Trait-associated SNPs are more likely to be eQTLs: annotation to enhance discovery from GWAS. *PLoS Genet* 2010;6:e1000888.
44. Ni Z, Olsen JB, Guo X, Zhong G, Ruan ED, Marcon E, et al. Control of the RNA polymerase II phosphorylation state in promoter regions by CTD interaction domain-containing proteins RPRD1A and RPRD1B. *Transcription* 2011;2:237–42.
45. Morales JC, Richard P, Rommel A, Fattah FJ, Motea EA, Patidar PL, et al. Kub5-Hera, the human Rtt103 homolog, plays dual functional roles in transcription termination and DNA repair. *Nucleic Acids Res* 2014;42:4996–5006.
46. Patidar PL, Motea EA, Fattah FJ, Zhou Y, Morales JC, Xie Y, et al. The Kub5-Hera/RPRD1B interactome: a novel role in preserving genetic stability by regulating DNA mismatch repair. *Nucleic Acids Res* 2016;44:1718–31.
47. Sawant A, Kothandapani A, Zhitkovich A, Sobol RW, Patrick SM. Role of mismatch repair proteins in the processing of cisplatin interstrand cross-links. *DNA Repair (Amst)* 2015;35:126–36.
48. Zhang Y, Liu C, Duan X, Ren F, Li S, Jin Z, et al. CREPT/RPRD1B, a recently identified novel protein highly expressed in tumors, enhances the beta-catenin/TCF4 transcriptional activity in response to Wnt signaling. *J Biol Chem* 2014;289:22589–99.
49. Ille F, Sommer L. Wnt signaling: multiple functions in neural development. *Cell Mol Life Sci* 2005;62:1100–8.
50. Simonetti M, Agarwal N, Stosser S, Bali KK, Karaulanov E, Kamble R, et al. Wnt-Fzd signaling sensitizes peripheral sensory neurons via distinct non-canonical pathways. *Neuron* 2014;83:104–21.
51. Mellion M, Gilchrist JM, de la Monte S. Alcohol-related peripheral neuropathy: nutritional, toxic, or both? *Muscle Nerve* 2011;43:309–16.
52. Ziegler D. Current concepts in the management of diabetic polyneuropathy. *Curr Diabetes Rev* 2011;7:208–20.
53. Grov EK, Fossa SD, Bremnes RM, Dahl O, Klepp O, Wist E, et al. The personality trait of neuroticism is strongly associated with long-term morbidity in testicular cancer survivors. *Acta Oncol* 2009;48:842–9.

# Clinical Cancer Research

## Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer

M. Eileen Dolan, Omar El Charif, Heather E. Wheeler, et al.

*Clin Cancer Res* 2017;23:5757-5768. Published OnlineFirst June 13, 2017.

**Updated version** Access the most recent version of this article at:  
[doi:10.1158/1078-0432.CCR-16-3224](https://doi.org/10.1158/1078-0432.CCR-16-3224)

**Supplementary Material** Access the most recent supplemental material at:  
<http://clincancerres.aacrjournals.org/content/suppl/2017/06/13/1078-0432.CCR-16-3224.DC1>

**Cited articles** This article cites 52 articles, 11 of which you can access for free at:  
<http://clincancerres.aacrjournals.org/content/23/19/5757.full#ref-list-1>

**Citing articles** This article has been cited by 4 HighWire-hosted articles. Access the articles at:  
<http://clincancerres.aacrjournals.org/content/23/19/5757.full#related-urls>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link  
<http://clincancerres.aacrjournals.org/content/23/19/5757>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.